Aravive — Investor Presentation (September 2022)
39 slides from Aravive's investor presentation, Sep 27, 2022
Slide 1: Developing Transformative Targeted Cancer Therapeutics
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation September 2022 NASDAQ: ARAV
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that may discuss Aravive's plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward-looking statements generally include statements that
Slide 3: Batiraxcept: A Novel Late-Stage Clinical Program Differentiated from Other Cancer Therapies
Batiraxcept: A Novel Late-Stage Clinical Program Differentiated from Other Cancer Therapies @. — GASB/AXL signaling drives metastasis and Fast-track designation granted by the FDA for drug-resistance. ARAV is the only company platinum-resistant ovarian cancer; currently 4 targeting GAS6. in registra
Slide 4: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers
GAS6 & AXL Expression Associated with Poor Survival in Many Cancers AXL expressed in >70% of ovarian, pancreatic, breast, kidney, and uterine cancers” “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis” WW et Mleaarinighsof Gse/Tamin tence Secopmentat ropes cel Dra
Slide 5: GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors
GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors and Expression Associated with Poor Survival in Many Cancers 4 The GAS6/AXL pathway mediates multiple steps of metastasis. + AXL activation regulates downstream signaling, including the JAK/STAT pathway, Ras/MEK/Erk1/2 pathway, and PI3K/A
Slide 6: Effective Treatment of Human Tumors Requires Drugs that Target Non-metastatic and Metastatic Tumor Cells
Effective Treatment of Human Tumors Requires Drugs that Target Non-metastatic and Metastatic Tumor Cells + Batiraxcept demonstrates single agent activity in preclinical models which have homogeneous, metastatic tumor cells + Human tumors display epithelia-mesenchymal heterogeneity '\2.° ~ Cells with
Slide 7: GAS6/AXL Signaling: High Affinity Decoy Receptor is the Best Approach
GAS6/AXL Signaling: High Affinity Decoy Receptor is the Best Approach for Potent and Selective Inhibition Tyrosine Kinase Inhibitor AXL or GAS6 Antibody UA RT EPS WY Hot Ho + Selectivity limited by RTK homology + Requires @ mAB affinity that competes + Binds more tightly to GASG than WT AXL wih rece
Slide 8: Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor
Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhi Modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6 + ~200 fold greater affinity for human GAS6 compared to native AXL receptor + Preclinical data demonstrated relationship between affinity
Slide 9: Experienced Management and Board of Directors
Experienced Management and Board of Directors SENIOR MANAGEMENT Lebolel ofthe Board ceo cro no Bom pda PUD DART S80 Ge, PD, Ain Homme CPA! ben Se A. BOARD OF DIRECTORS AHA Exec Chatman ofthe Board Dictor Director rector rector rector rector rector FredEahelman,PhamO. Amato locde,PhD. Petrfio,M.O., J
Slide 10: Aravive Pipeline
Aravive Pipeline Opportunity for Expansion into Additional Indications and Drug Combinations Indication Preclinical Phase 1 Phase 2 Phase 3 Batiraxcept (AVB-500) ‘OVARIAN CANCER Platinum Resistant (oatraxcept + pacitaxel) jignation in U.S., Orphan Designation in EU CLEAR CELL RENAL CANCER + 1 Line (
Slide 11: Batiraxcept May Unlock ~$3B in Global Revenue Across PROC, Renal and Pancreatic Tumors
Batiraxcept May Unlock ~$3B in Global Revenue Across PROC, Renal and Pancreatic Tumors, with PROC Representing a Near-term Growth Driver Potential for Large Total Accessible Market Across Multiple Tumor Types Marketing Estimates / Indication Estimated Treatable Patients PROC + 4K bev naive (USA) + 5
Slide 12: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
Slide 13: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies
Summary of Phase 1a Healthy Volunteer and 1b PROC Studies Phase 1a single ascending dose and rej + 43 subjects participated; 42 dosed + Batiraxcept was well-tolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs No anti-drug antibodies (ADA) + 10 mg/kg (IV) administered every other week suppresse
Slide 14: Batiraxcept + Paclitaxel in P1b PROC
Batiraxcept + Paclitaxel C in Pib PROC Modeling Identified RP2D of 15 mg/kg for PROC + Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile + Exposure-response relationship identified by unsupervised ‘computer analysis ~ Statisti
Slide 15: Exposure-Response Modeling Consistent with Preclinical Data
Exposure-Response Modeling Consistent with Preclinical Data + Exposure-Response modeling of P1b PROC and P1b ccRCC demonstrates a plateau at 20mg/kg + Preclinical data from ovarian cancer model demonstrated plateau from 10 to 20mg/kg (equate to lower doses in humans) — No toxicity issues identified
Slide 16: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients
Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3+ Line of Therapy; Literature Demonstrates 85% of Patients on their 3 Line of Therapy have Progressive Disease by their First CT Scan’ PPS Monts for PerProtocol 10 mg/kg and 15 mg/kg A
Slide 17: Evidence of Batiraxcept to Maintain Response following Discontinuation of Chemotherapy
Evidence of Batiraxcept to Maintain Response following Discontinuation of Chemotherapy from P1b PROC PROC 1B: batiraxcept monotherapy (15mg/kg) maintained complete response in 1 patient for 8 months and batiraxcept monotherapy (10mg/kg) maintained partial responses for 5 months in 2 patients followi
Slide 18: Promising Responses in Patients in Later Lines of Therapy and <3 Month Platinum-Free Interval
Promising Responses in Patients in Later Lines of Therapy and <3 Month Platinum-Free Interval Compared to Literature Invasive Tumors Resistant to Multiple Lines of Therapy Expected to Be Dependent on the GAS6/AXL Pathway CLINICAL RESPONSE, CLINICAL RESPONSE OF BATIRAXCEPT+ set OF CHEMOTHERAPY IN 2 C
Slide 19: Batiraxcept Phase 3 Registrational Trial Design in PROC
Batiraxcept Phase 3 Registrational Trial Design in PROC (ClinicalTrials.gov NCT04729608) + FDA Feedback: If positive, trial could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time + Endpoint Assessme FS per RECIST V1.1; radiological imaging every
Slide 20: Market Research Suggests Batiraxcept Would Fill an Unmet Need in PROC
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PROC Treatment Paradigm “Platinum resistantpatients are in need of new targeted treatment options." Healthcare Provider “To see this levelof safety with the improved efficacy is impressive —| certainly woul
Slide 21: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Slide 22: Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC
Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC (NCT04300140) Population: * 26 patients (P1b) and 55 patients (P2; currently enrolling) Phase2 + Histologically confirmed metastatic ceRCC and progressed on/after a frontline treatment regimen + Patients previously treated with cabozantinib
Slide 23: P1b ccRCC Study: Safety Profile Consistent with Cabozantinib
P1b ccRCC Study: Safety Profile Consistent with the Established Safety Profile for Cabozantinib 45 mglkg PAb 20 mgikg Pb AME Eaton Patients Patients 8) (N= 16) (N=10) Batiraxcept Related Deaths ° ° ° Grade 3 Adverse Events (AES), 5 (19.2%) 3 (18.8%) 2 (20%) related to Batiraxcept Events: HTN Events:
Slide 24: P1b ccRCC: Clinical Activity of Batiraxcept + Cabozantinib
P1b ccRCC: Clinical Activity of Batiraxcept + Cabozantinib Efficacy Evaluable Best Response Confirmed Partial Response 11 (42%) 8 (50%) 3 (30%) Confirmed Stable Disease 11 (42%) 6 (38%) 5 (60%) Progressive Disease ? 4 (15%) 2 (12%) 2 (20%) ‘9-month Progression-Free 65% 61% 79% Survival 7-month Durat
Slide 25: P1b ccRCC: Pretreatment Serum sAXL/GAS6 is a Potential Biomarker
P1b ccRCC: Pretreatment Serum sAXL/GASG6 is a Potential Biomarker with 100% Negative Predictability Best Response AllP1b Patients P1b15mg/kg Pb 20 mg/kg (n=25) 1 (n=16) (n=9) 1 PR for Patients with low sAXL/GAS6 0/5 (0%) 0/4 (0%) 0/1 (0%) Confirmed PR for Patients with high 41/20 (65%) 8/12 (67%) 2
Slide 26: Batiraxcept Phase 2/3 Registrational Trial Design in ccRCC
Batiraxcept Phase 3 Registrational Trial Design in ccRCC FDA Recommendation: Integrated P2/3 study with interim analyses to look at futility in the biomarker low population and ORR for potential accelerated approval with PFS endpoint for full approval. Full protocol and statistical plan in preparati
Slide 27: Market Research Suggests Batiraxcept Would Fill an Unmet Need in ccRCC
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Curre' Paradigm Improved2L Improved efficacy overcabozentinib was seen as practice- Efficacyover changing andmayleadto less 1L cabo use in orderto Cabozantinib preservefor 2L Targeted Batiraxcept'sbiomarker-driven
Slide 28: Batiraxcept: Pancreatic Adenocarcinoma
Batiraxcept: Pancreatic Adenocarcinoma
Slide 29: Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma
Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma (NCT04983407) P4b Population: + Patients (N~20) with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab- paclitaxel (Abraxane®) as first-line treatment Phase 1b Phas
Slide 30: Safety Profile Consistent with Gemcitabine + nab-Paclitaxel in P1b PDAC
Safety Profile Consistent with the Established Safety Profile for Gemcitabine + nab Paclitaxel or Underlying Disease In P1b PDAC Study All P1b Patients 45 mg/kg Batiraxcept + Gemcitabine+ nab- Paclitaxel (N= 21) Batiraxcept-Related Deaths CY) Grade 3 Adverse Events (AEs), related to 6 (29%) Batiraxc
Slide 31: Initial Anti-Tumor Activity from Phase 1b PDAC Trial
Initial Anti-Tumor Activity from Phase 1b PDAC Trial: 15 mg/kg Batiraxcept + Gemcitabine+ nab-Paclitaxel Best Response All P1b Patients (N= 21) Confirmed Partial Response 6 (29%) Stable Disease 5 (24%) Progressive Disease 5 (24%) Not Evaluable 3 (14%) Not Applicable (died before any post-baseline sc
Slide 32: P1b PDAC: Exposure-Response Relationship Identified
P1b PDAC: Exposure-Response Relationship Identified Higher Batiraxcept Doses May be Needed to Saturate the Target and Increase the Proportion of Patients whose Trough Levels are Above the MEC + Exposure-response analysis | 2" revealed minimum efficacious O_O EO concentration (MEC) of ———————"._.- ba
Slide 33: P1b PDAC: Clinical Activity by MEC Status
P1b PDAC: Clinical Activity by MEC Status ORR higher and mPFS longer in Patients who Achieve MEC Efficacy Evaluable Ue Made ia (N=9)* Best Response Partial Response 5 (56%) 4 (11%) Stable Disease 2 (22%) 2 (22%) Progressive Disease ) 4 (44%) NE 1 (11%) 2 (22%) NA (no scans) 4 (11%) 0 Progression-Fre
Slide 34: Next Steps for PDAC
Next Steps for PDAC * To identify the RP2D: —Amend the current P1b study to test 6 patients at 20 mg/kg batiraxcept + gemcitabine + nab-paclitaxel to determine if: * a greater proportion of patients have batiraxcept trough levels above the minimum efficacious exposure; + clinical activity is higher
Slide 35: Market Research Suggests Batiraxcept Would Fill an Unmet Need in PDAC
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PDAC Treatment Paradigm “Efficacy inthe base caseis similarto ‘IRINOX, like that it is more Note: physicians’ comments based on P1bdata 7
Slide 36: Upcoming Key Milestones
Upcoming Key Milestones Initiate 20mg/kg cohort of P3 PROC Top Line PDAC Study balls Potential Approval of safety ani — ‘Submit BLA for PROC, if PROC BLA safety and Preliminary trial successful — Activity from P2 eeRCC Trial ditional F2 ecROC Teal — FP .-§ — Updated PDAC and Complete Enrollment of P
Slide 37: Financial Summary
Financial Summary $46.8 30.5 Million* No Debt cash Runway Million* Shares xpected to Fun: Cash and Cash Outstanding Base Operating Eauivalene Plan into Q1 2023 quivale! ata as oteca2022 63 a
Slide 38: Dedicated to Developing Innovative Treatments for Life-Threatening Diseases
Dedicated to Developing Innovative Treatments for Life-Threatening Diseases to Increase Patient Survival Batiraxcept development program focused on difficult-to-treat cancers with high unmet medical needs Proprietary, differentiated first-class therapeutic targeting and inhibiting GASG/AXL signaling
Slide 39: Developing Transformative Targeted Cancer Therapeutics
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation September 2022 NASDAQ: ARAV